Alflutop solution for injection, 2 ml No. 5

• Primary and secondary osteoarthritis of various localization (coxarthrosis, gonarthrosis, arthrosis of small joints);

• spondylosis;

• osteochondrosis.

In case of polyosteoarthrosis and osteochondrosis, the drug is injected deeply into the / m at 1 ml / day. The course of treatment is 20 injections (1 injection per day for 20 days).

With a predominant lesion of large joints, the drug is administered intra-articularly by 1-2 ml into each joint with an interval of 3-4 days. The course of treatment is 5-6 injections into each joint.

A combination of intramuscular and intra-articular administration is possible. It is advisable to repeat the course of treatment 6 months after consulting a doctor.

1 ml

bioactive concentrate from small sea fish (North Sea sprat (Sprattus sprattus sprattus), herring family (Clupeidae); Black Sea whiting (Odontogadus merlangus euxinus), cod family (Gadidae); Black sea gum (Alosida tana), family Black Sea (Engraulis encrassicholus ponticus), anchovy family (Engraulidae), obtained by extraction followed by deproteinization and delipidization 0.1 ml

Excipients: phenol - no more than 0.005 g, water d / i - up to 1 ml.

• Hypersensitivity to the components of the drug;

• pregnancy;

• lactation period (breastfeeding);

• age up to 18 years (due to the lack of clinical data in this category of patients).

pharmachologic effect

Alflutop is a chondroprotector, the active component of which is a bioactive concentrate from small sea fish. The concentrate contains mucopolysaccharides (chondroitin sulfate), amino acids, peptides, sodium, potassium, calcium, magnesium, iron, copper and zinc ions. Alflutop prevents the destruction of macromolecular structures of normal tissues, stimulates recovery processes in interstitial tissue and articular cartilage tissue, which explains its analgesic effect. The anti-inflammatory effect and tissue regeneration are based on the inhibition of the activity of hyaluronidase and the normalization of the biosynthesis of hyaluronic acid. Both of these effects are synergistic and cause the activation of regenerative processes in tissues, in particular, the restoration of the cartilage structure.

Pharmacokinetics

Data on the pharmacokinetics of the drug Alflutop are not provided.

Side effect

Rarely: itchy dermatitis, skin redness, burning sensation at the injection site, short-term myalgia. Very rare: anaphylactic reactions. Frequency unknown: transient increase in pain syndrome (with intra-articular administration).

Application during pregnancy and lactation

The drug is contraindicated for use during pregnancy and lactation (breastfeeding).

Application in children

Contraindicated under the age of 18 (due to the lack of clinical data in this category of patients).

special instructions

In case of individual intolerance to seafood (sea fish), the risk of developing allergic reactions increases.

Influence on the ability to drive vehicles and use mechanisms

The use of the drug does not affect the ability to perform potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions (driving, working with moving mechanisms, the work of a dispatcher and an operator).

Overdose

Overdose increases dose-dependent adverse drug reactions.

Drug interactions

Until now, drug interactions with Alflutop have not been identified.